Navigating the new normal: Debating the place of high-efficacy vs escalation treatment approaches in MS
Meeting date: 18 November 2020
Chair: Professor Nikos Evangelou, Associate Professor of Neurology, University of Nottingham
For: Dr Waqar Rashid, Consultant Neurologist, St George’s University Hospital
Against: Dr David Paling, Consultant Neurologist, Sheffield Teaching Hospitals
Considering the latest scientific evidence, clinical experiences and our changing world, esteemed MS experts, Dr Waqar Rashid and Dr David Paling, debate whether in the new normal, treatment with disease-modifying therapies should be initiated using high-efficacy treatments in the majority of MS patients.
Following the debate, Professor Nikos Evangelou leads an open educational discussion to explore the challenging decision process in managing MS treatment in today’s new normal and beyond.
This meeting was organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.